A new paper presents preliminary evidence that a new vaccine candidate, designed to boost immunity in already immunized individuals, and containing the adjuvanted Beta spike variant protein antigen, can induce a potent cross-neutralizing antibody response in non-human primate models that is detectable for up to three months.
An intranasal vaccine durably protects against SARS-CoV-2 variants in mice - ScienceDirect
PDF) Beta variant COVID-19 protein booster vaccine elicits durable cross- neutralization against SARS-CoV-2 variants in non-human primates
Frontiers Review of therapeutic mechanisms and applications based on SARS-CoV-2 neutralizing antibodies
Frontiers Analysis of the protective efficacy of approved COVID-19 vaccines against Omicron variants and the prospects for universal vaccines
Structural and biochemical rationale for Beta variant protein booster vaccine broad cross-neutralization of SARS-CoV-2
Variants of SARS CoV-2: mutations, transmissibility, virulence, drug resistance, and antibody/vaccine sensitivity
Frontiers Vaccine-Associated Enhanced Disease and Pathogenic Human Coronaviruses
mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant - ScienceDirect
Role of the humoral immune response during COVID-19: guilty or not guilty? - Mucosal Immunology
COVID-19 vaccine - Wikipedia
Variable loss of antibody potency against SARS-CoV-2 B.1.1.529 (Omicron)
COVID-19 vaccine update: vaccine effectiveness, SARS-CoV-2 variants, boosters, adverse effects, and immune correlates of protection, Journal of Biomedical Science
